{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:50:57Z","timestamp":1781319057037,"version":"3.54.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.pbb.2012.12.002","type":"journal-article","created":{"date-parts":[[2012,12,9]],"date-time":"2012-12-09T04:18:16Z","timestamp":1355026696000},"page":"717-722","source":"Crossref","is-referenced-by-count":20,"title":["Chronic olanzapine administration in rats: Effect of route of administration on weight, food intake and body composition"],"prefix":"10.1016","volume":"103","author":[{"given":"Steve","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araba","family":"Chintoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adria","family":"Giacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2012.12.002_bb0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","article-title":"Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?","volume":"29","author":"Aichhorn","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.pbb.2012.12.002_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity (Silver Spring)"},{"issue":"Suppl. 7","key":"10.1016\/j.pbb.2012.12.002_bb0015","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pbb.2012.12.002_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4088\/JCP.v63n0312a","article-title":"Mechanisms of weight gain induced by antipsychotic drugs","volume":"63","author":"Baptista","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0091-3057(87)90340-6","article-title":"Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?","volume":"27","author":"Baptista","year":"1987","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2012.12.002_bb0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"Baptista","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2012.12.002_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0014-2999(02)01816-2","article-title":"The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?","volume":"447","author":"Baptista","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0035","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.pnpbp.2004.08.001","article-title":"Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection","volume":"28","author":"Baptista","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/met.2004.2.290","article-title":"The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management","volume":"2","author":"Baptista","year":"2004","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.pbb.2012.12.002_bb0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0065","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pbb.2012.12.002_bb0060","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2012.12.002_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pbb.2012.12.002_bb0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2008.06.006","article-title":"Insulin resistance following continuous, chronic olanzapine treatment: an animal model","volume":"104","author":"Chintoh","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pbb.2012.12.002_bb0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pbb.2012.12.002_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0731-7085(95)01651-1","article-title":"Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection","volume":"14","author":"Chiu","year":"1996","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pbb.2012.12.002_bb0095","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lfs.2007.08.009","article-title":"Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats","volume":"81","author":"Choi","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.pbb.2012.12.002_bb0100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1176\/appi.ps.57.8.1132","article-title":"Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997\u20132004","volume":"57","author":"Citrome","year":"2006","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pbb.2012.12.002_bb0105","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0110","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/070674370404901106","article-title":"Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome","volume":"49","author":"Cohn","year":"2004","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0115","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/070674370605100608","article-title":"Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report","volume":"51","author":"Cohn","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2012.12.002_bb0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0269881106069637","article-title":"Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities","volume":"21","author":"Cooper","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0120","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pnpbp.2007.09.012","article-title":"Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain","volume":"32","author":"Cooper","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0135","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat","volume":"158","author":"Eder","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881104042613","article-title":"Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats","volume":"18","author":"Fell","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00213-005-0131-3","article-title":"Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats","volume":"182","author":"Fell","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2012.12.002_bb0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","article-title":"The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats","volume":"194","author":"Fell","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2012.12.002_bb0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0269881107082287","article-title":"Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats","volume":"22","author":"Fell","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0160","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models of the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/WNF.0b013e3181f0ec33","article-title":"Visceral and subcutaneous fat in patients treated with olanzapine: a case series","volume":"33","author":"Gilles","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pbb.2012.12.002_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-002-1368-8","article-title":"Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat","volume":"167","author":"Hartfield","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl. 12","key":"10.1016\/j.pbb.2012.12.002_bb0185","first-page":"18","article-title":"Weight gain with atypical antipsychotics: evidence and insights","volume":"68","author":"Henderson","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0195","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/00048670903489890","article-title":"Patterns of antipsychotic medication use in Australia 2002\u20132007","volume":"44","author":"Hollingworth","year":"2010","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2012.12.002_bb0205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/j.1552-4604.1994.tb01995.x","article-title":"Clinical pharmacokinetics of antipsychotics","volume":"34","author":"Javaid","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0006-3223(99)00208-5","article-title":"Neuroleptic discontinuation in clinical and research settings: scientific issues and ethical dilemmas","volume":"46","author":"Jeste","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0215","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00213-005-0081-9","article-title":"Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats","volume":"182","author":"Kalinichev","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2012.12.002_bb0220","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00008877-200605000-00009","article-title":"Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine","volume":"17","author":"Kalinichev","year":"2006","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0225","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin\u2013dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0230","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0235","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2012.12.002_bb0240","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pbb.2012.12.002_bb0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0250","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/schbul\/sbq058","article-title":"Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?","volume":"38","author":"Kirkpatrick","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pbb.2012.12.002_bb0255","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1192\/bjp.184.47.s64","article-title":"Diabetes mellitus and schizophrenia: historical perspective","volume":"47","author":"Kohen","year":"2004","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.pbb.2012.12.002_bb0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-381328-2.00011-0","article-title":"Animal models of tardive dyskinesia","volume":"98","author":"Kulkarni","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0091-3057(01)00630-X","article-title":"Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol","volume":"71","author":"Lee","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2012.12.002_bb0270","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.medengphy.2008.03.006","article-title":"In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model","volume":"31","author":"Luu","year":"2009","journal-title":"Med Eng Phys"},{"key":"10.1016\/j.pbb.2012.12.002_bb0275","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pbb.2012.12.002_bb0285","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbr.2005.05.004","article-title":"Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection","volume":"163","author":"Minet-Ringuet","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2012.12.002_bb0280","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.appet.2006.01.008","article-title":"Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration","volume":"46","author":"Minet-Ringuet","year":"2006","journal-title":"Appetite"},{"key":"10.1016\/j.pbb.2012.12.002_bb0290","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00213-006-0433-0","article-title":"A model for antipsychotic-induced obesity in the male rat","volume":"187","author":"Minet-Ringuet","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2012.12.002_bb0295","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/14622416.7.6.863","article-title":"Genetics of antipsychotic treatment emergent weight gain in schizophrenia","volume":"7","author":"Muller","year":"2006","journal-title":"Pharmacogenomics"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2012.12.002_bb0300","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2012.12.002_bb0305","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics: a comprehensive database analysis","volume":"110","author":"Parsons","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pbb.2012.12.002_bb0330","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.09.009","article-title":"Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain","volume":"551","author":"Patil","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","article-title":"Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human","volume":"75","author":"Pouzet","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2012.12.002_bb0340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/10401230600801234","article-title":"Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies","volume":"18","author":"Ramaswamy","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0345","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.npp.1301093","article-title":"Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats","volume":"32","author":"Raskind","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2012.12.002_bb0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31802e5126","article-title":"Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002","volume":"27","author":"Reist","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0355","first-page":"275","article-title":"Understanding antipsychotic \u201catypicality\u201d: a clinical and pharmacological moving target","volume":"28","author":"Remington","year":"2003","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pbb.2012.12.002_bb0360","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mhpa.2009.01.003","article-title":"From mice to men: what can animal models tell us about mental health and physical activity?","volume":"2","author":"Remington","year":"2009","journal-title":"Ment Health Phys Act"},{"key":"10.1016\/j.pbb.2012.12.002_bb0365","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pbb.2011.07.019","article-title":"Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations","volume":"100","author":"Remington","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2012.12.002_bb0370","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 21","key":"10.1016\/j.pbb.2012.12.002_bb0375","first-page":"16","article-title":"Weight gain associated with use of psychotropic medications","volume":"60","author":"Sachs","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0380","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.lfs.2011.02.014","article-title":"Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats","volume":"88","author":"Shobo","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.pbb.2012.12.002_bb0385","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","article-title":"Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia","volume":"24","author":"Spelman","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.pbb.2012.12.002_bb0390","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","article-title":"Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution","volume":"585","author":"van der Zwaal","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2012.12.002_bb0395","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0028-1103293","article-title":"Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund","volume":"42","author":"Weinbrenner","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2012.12.002_bb0400","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1345\/aph.1L155","article-title":"Antipsychotic medication utilization trends among Texas veterans: 1997\u20132002","volume":"42","author":"Yang","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pbb.2012.12.002_bb0405","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br J Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305712003267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305712003267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T17:19:10Z","timestamp":1562433550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305712003267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0091305712003267"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2012.12.002","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}